Zydus gets U.S. FDA nod for generic BP tablet
Zydus Lifesciences subsidiary Zydus Worldwide DMCC has received final approval from the U.S. Food and Drug Administration to market Selexipag Tablets in different strengths. Indicated in adults for treatment of pulmonary arterial hypertension (PAH), the reference listed drug of the approved product is Uptravi tablets. Since it was one of the first applicants to submit […]
Continue Reading